A theme covering fluctuations in performance in the pharmaceutical-related business, including declines in revenue and segment profit against a backdrop of sales and shipment trends for anticancer drugs and syringe products. It also includes subsequent shifts to higher revenue and profit driven by increased shipments of newly contracted products and other factors.